

C7 vs Pathway Expression

	C7		IC(Δ)	P-val	FDR
	SENESE_HDAC2_TARGETS_UP		0.794(0.004)	2.62e-06	5.66e-06
	SENESE_HDAC1_TARGETS_UP		0.783(0.005)	2.62e-06	5.66e-06
	BROWNE_HCMV_INFECTION_2HR_DN		0.782(0.004)	2.62e-06	5.66e-06
	XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR		0.779(0.005)	2.62e-06	5.66e-06
	SENESE_HDAC1_AND_HDAC2_TARGETS_UP		0.774(0.005)	2.62e-06	5.66e-06
	AMIT_EGF_RESPONSE_480_HELA		0.771(0.006)	2.62e-06	5.66e-06
	BMI1_DN_MEL18_DN.V1		0.765(0.006)	2.62e-06	5.66e-06
	AMIT_EGF_RESPONSE_480_MCF10A		0.763(0.005)	2.62e-06	5.66e-06
	MEL18_DN.V1		0.759(0.007)	2.62e-06	5.66e-06
	KIM_WT1_TARGETS_12HR_DN		0.759(0.006)	2.62e-06	5.66e-06
	AMIT_EGF_RESPONSE_240_HELA		0.755(0.006)	2.62e-06	5.66e-06
	HUANG_DASATINIB_RESISTANCE		0.753(0.007)	2.62e-06	5.66e-06
	XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP		0.748(0.006)	2.62e-06	5.66e-06
	HUANG_DASATINIB_RESISTANCE_UP		0.744(0.007)	2.62e-06	5.66e-06
	KRAS.DF.V1_UP		0.738(0.005)	2.62e-06	5.66e-06
	PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2		0.736(0.005)	2.62e-06	5.66e-06
	NIELSEN_LEIOMYOSARCOMA		0.734(0.007)	2.62e-06	5.66e-06
	FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_UP		0.731(0.006)	2.62e-06	5.66e-06
	BMI1_DN.V1		0.731(0.006)	2.62e-06	5.66e-06
	ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN		0.730(0.006)	2.62e-06	5.66e-06
	BROWNE_HCMV_INFECTION_10HR		-0.638(0.007)	2.62e-06	1.66e-05
	GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT		-0.646(0.008)	2.62e-06	1.66e-05
	LEE_LIVER_CANCER_SURVIVAL		-0.654(0.008)	2.62e-06	1.66e-05
	BROWNE_HCMV_INFECTION_8HR		-0.655(0.007)	2.62e-06	1.66e-05
	RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY		-0.657(0.009)	2.62e-06	1.66e-05
	ESC_V6.5_UP_EARLY.V1		-0.658(0.008)	2.62e-06	1.66e-05
	GHO_ATF5_TARGETS		-0.659(0.008)	2.62e-06	1.66e-05
	PETROVA_PROX1_TARGETS		-0.663(0.009)	2.62e-06	1.66e-05
	BROWNE_HCMV_INFECTION_14HR		-0.665(0.009)	2.62e-06	1.66e-05
	RIGGI_EWING_SARCOMA_PROGENITOR		-0.671(0.007)	2.62e-06	1.66e-05
	RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY		-0.672(0.008)	2.62e-06	1.66e-05
	WEINMANN_ADAPTATION_TO_HYPOXIA		-0.693(0.007)	2.62e-06	1.66e-05
	BROWNE_HCMV_INFECTION_20HR		-0.695(0.006)	2.62e-06	1.66e-05
	KUNINGER_IGF1_VS_PDGFB_TARGETS		-0.697(0.006)	2.62e-06	1.66e-05
	SRC_UP.V1		-0.711(0.007)	2.62e-06	1.66e-05
	OSADA_ASCL1_TARGETS		-0.737(0.008)	2.62e-06	1.66e-05
	CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL		-0.741(0.007)	2.62e-06	1.66e-05
	PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD		-0.742(0.008)	2.62e-06	1.66e-05
	KOBAYASHI_EGFR_SIGNALING_6HR		-0.752(0.005)	2.62e-06	1.66e-05
	REN_ALVEOLAR_RHABDOMYOSARCOMA		-0.762(0.006)	2.62e-06	1.66e-05